Table 1. Ongoing randomized controlled trials of TACE combined with immunotherapy.
| Trial (NCT number) | Enrollment | Population under study (BCLC stage) | Therapies under comparison | Primary endpoint(s) |
|---|---|---|---|---|
| EMERALD-1 (NCT03778957) | 710 | Candidates for first TACE (BCLC-B) | TACE plus durvalumab plus bevacizumab vs. TACE plus durvalumab vs. TACE plus placebo | PFS for placebo vs. combination |
| CHECKMATE-74W (NCT04340193) | 765 | Candidates for first TACE (BCLC-B) | TACE plus nivolumab plus ipilimumab vs. TACE plus nivolumab vs. TACE | OS and TTTP |
| LEAP-012 (NCT04246177) | 950 | Candidates for first TACE (BCLC-B) | TACE plus pembrolizumab plus lenvatinib vs. TACE plus oral placebo plus IV placebo | OS and PFS |
| TACE-3 (NCT04268888) | 522 | Candidates for first TACE (BCLC-B) | DEB-TACE plus nivolumab vs. DEB-TACE | OS (TTTP for the phase II portion) |
| RENOTACE (NCT04777851) | 496 | Candidates for first TACE (BCLC-B) | Regorafenib plus nivolumab vs. TACE | PFS |
| ABC-HCC (NCT04803994) | 434 | Candidates for first TACE (BCLC-B) | Atezolizumab plus bevacizumab vs. TACE | Time to failure of treatment |
BCLC, Barcelona Clinic Liver Cancer; DEB-TACE, drug-eluting beads transarterial chemoembolization; OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization; TTTP, time to TACE progression.